Explore
Validate
Learn24849-1-AP
antibody from Proteintech Group
Targeting: VSIR
B7-H5, B7H5, C10orf54, Dies1, GI24, PD-1H, SISP1, VISTA
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 24849-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- VISTA antibody
- Antibody type
- Polyclonal
- Description
- VISTA antibody (Cat. #24849-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references VISTA promotes ovarian cancer progression through activation of NF-κB pathway and tumor microenvironment reprogramming.
Machine learning-driven prediction of immune checkpoint inhibitor responses against cholangiocarcinoma: a bile biopsy perspective.
Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells.
Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression.
Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis.
Liu S, Zhou Q, Ji F, Zhu T, Ding B, Xu J, Zhang T, Lin H, Shen Y
Journal of ovarian research 2026 Mar 20;19(1)
Journal of ovarian research 2026 Mar 20;19(1)
Machine learning-driven prediction of immune checkpoint inhibitor responses against cholangiocarcinoma: a bile biopsy perspective.
Zhang D, Li X, Wang Z, Fan J, Yang Y, Han S, Sun W, Wang D, Zhou S, Liu Z, Chen S, Yang Y, Zhu Y, Lu Z
Frontiers in immunology 2025;16:1614683
Frontiers in immunology 2025;16:1614683
Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells.
Abooali M, Lei X, Yasinska IM, Schlichtner S, Hussain R, Siligardi G, Gianga TM, Berger SM, Cholewa D, Gibbs BF, Fasler-Kan E, Sumbayev VV
Immuno-oncology technology 2025 Dec;28:101533
Immuno-oncology technology 2025 Dec;28:101533
Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression.
Zhang Q, Cao W, Yang C, Hong L, Geng S, Han H, Zhong C
The Journal of nutritional biochemistry 2023 Feb;112:109226
The Journal of nutritional biochemistry 2023 Feb;112:109226
Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis.
Liu Y, Zhang J, Wang Z, Zhang X, Dai Z, Wu W, Zhang N, Liu Z, Zhang J, Luo P, Wen Z, Yu J, Zhang H, Yang T, Cheng Q
Frontiers in cell and developmental biology 2022;10:821649
Frontiers in cell and developmental biology 2022;10:821649
No comments: Submit comment
No validations: Submit validation data